Please login to the form below

Not currently logged in
Email:
Password:

Dr Christian Itin joins Cytos Biotechnology as CEO

He moves to the Swiss biotech from Micromet

Cytos Biotechnology CEO Dr Christian ItinSwiss biotech company Cytos Biotechnology has appointed Dr Christian Itin to be its new CEO.

He has also been elected to Cytos' board of directors and will be proposed as its new chairman, succeeding Dr Thomas Hecht, at an extraordinary shareholders meeting next month.

Dr Itin joins Cytos from Micromet, where he served as CEO for eight years until the biopharmaceutical company was acquired by Amgen earlier this year for $1.2bn.

In total he spent 13 years in senior management roles at Micromet, prior to which he co-founded US protein chip company Zyomyx.

Commenting on the appointment Dr Hecht said: “Christian is an experienced biotech leader with significant expertise and a proven track record and his appointment completes our restructuring of Cytos. We believe with his experience and skills that he is well positioned to shape Cytos' future.” 

Cytos' board will see a further change next month, when non-executive member, and its former chief financial officer Jakob Schlapbach will set down at the shareholder meeting.

18th October 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics